CRISPR Editing of U2OS Cells
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Center for Cancer Research, Massachusetts General Hospital, City University of Hong Kong, Harvard University
Protocol cited in 5 other protocols
Variable analysis
- Cas9 plasmid (750 ng)
- SgRNA plasmid (250 ng)
- T7E1 assay results
- GUIDE-seq experiment results
- Targeted deep sequencing results
- Cell lines (U2OS and U2OS.EGFP)
- Cell culture media (Advanced DMEM, 10% HI FBS, 2 mM GlutaMax, penicillin/streptomycin)
- Geneticin (400 µg/ml) for U2OS.EGFP cells
- Mycoplasma contamination testing (bi-weekly)
- Cell line identity validation (STR profiling and deep-sequencing)
- Cas9 plasmid co-transfected with sgRNA plasmid
- Cas9 plasmid co-transfected with a U6-null plasmid
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!